Adult Bovine Serum Market Analysis & Forecast: 2026-2033
The global adult bovine serum market size is expected to reach approximately USD 148.3 Mn in 2026 and USD 217.6 Mn by 2033, growing at a CAGR of 5.7% throughout the forecast period (2026-2033).
The serum extracted from blood of mature cattle and is commonly used as nutrient-rich supplement in cell culture media for biomedical and biological research is called as Adult Bovine Serum (ABS). It is extensively used to support growth and maintenance of mammalian cells in laboratory environments as it contains essential growth factors, proteins, hormones, and nutrients. The market is gaining strategic importance due to increasing demand for cell-based research, regenerative medicine, vaccine development, and biopharmaceutical production. The demand for high-quality bovine serum in laboratory and industrial applications is increasing due to rising investments in life-science research and expanding biotechnology & pharmaceutical industries.
|
Current Event |
Description and its Impact |
|
Expansion of Cell-based and Biopharmaceutical Research |
|
|
Innovation & Development of Serum-Free Cell Culture Alternatives |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Based on origin, North America-sourced is expected to lead the market, accounting for a revenue share of 45% in 2026. As the region has broad cattle population and organized slaughter activity have a structural advantage for developing adulty bovine serum which is obtained from comes from healthy slaughtered cattle 12 months or older. For instance, in January 2026, according to the data published by the U.S. Department of Agriculture (USDA), As of January 1, 2026, there were 86.2 million cattle and calves in the United States. As of January 1, 2026, there were 18.0 million heifers weighing 500 pounds or more. On January 1, 2026, there were 13.8 million cattle and calves on feed for the US slaughter market across all feedlots. Compared to the amount of 14.3 million head on January 1, 2025, the inventory has decreased by 3%. On January 1, 2026, 82.7 percent of the cattle on feed were housed in feedlots with a capacity of 1,000 or more head, a modest increase over the previous year. At 24.5 million head, the total number of calves under 500 pounds and other heifers and steers over 500 pounds (outside of feedlots) increased by 1% from January 1, 2025.
Moreover, due to strong abattoir and inspection infrastructure and high animal-health credibility makes North America-sourced the trusted origin. The U.S. is certified by WOAH as negligible risk for BSE, and Canada also holds negligible BSE risk status. The region's substantial inspected cattle base, advanced traceability systems, negligible BSE-risk status, strong slaughterhouse collection infrastructure, and high buyer confidence in regulatory compliance and batch consistency are the main factors supporting the dominance of the North America-sourced segment in the adult bovine serum market.
By application, research purpose segment is slated to account for a prominent market share of 60% in 2026. The research purpose segment is expected to dominate the market with a dominant share in 2026, due to high routine use in laboratory cell culture and cost-effective alternative to fetal bovine serum (FBS). The demand for serum is broader and more frequent than for specific uses, because serum is used in many different projects. Culture systems that use serum are extensively utilized in tissue engineering, drug testing, biotechnology research, and other related laboratory applications. Furthermore, due to large installed base of research institutions & testing labs and as adult bovine serum is fit for non-therapeutic with less regulation-heavy applications, the segment projects dominance in the market.
Based on end user, pharmaceutical & biotechnology companies segment led the global adult bovine serum market with share of 45% in 2026. The segment dominance is supported due to high rate of drug discovery, vaccine research, cell therapy, clinical pipeline expansion and biologics development. As compared to small research labs or academic institutes, the large-scale companies use products and services at a much larger commercial and pre-commercial scale, making their share higher. The pharmaceutical and biotechnological companies have strong focus on innovation pipelines and broad application scope. Rising shift toward regenerative medicine, biologics, and personalized therapies further strengthens demand from biotech and pharma companies, as they are the main commercial developers in these areas.
To learn more about this report, Download Free Sample
North America is expected to dominate the global adult bovine serum market, accounting for a share of 40% in 2026. North America has large cattle base and slaughter-linked raw material availability along with strong veterinary biologics and animal-health base. Veterinary biologics, including antisera, vaccinations, and diagnostic kits, are actively regulated by United States Department of Agriculture - Animal & Plant Health Inspection Service (USDA-APHIS), which has established an organized and substantial end-use ecosystem for culture materials obtained from cows throughout North America. Due to its extensive slaughter and cattle base, well-established facility for serum collection and processing, effective traceability and regulatory systems throughout the U.S. and Canada, and significant demand for biopharma and veterinary biologics, North America dominates the adult bovine serum market.
Expanding biotechnology and pharmaceutical companies in Asia Pacific region has driven growth of the adult bovine serum market over the forecast period. Moreover, rising government investments in life sciences in countries like China, India, and Japan and increasing cell culture research has driven the growth of the market. For instance, in January 2026, AstraZeneca UK based pharmaceutical company said that it would invest USD15 billion in China through 2030 to increase pharmaceutical manufacturing and research and development. In an effort to improve relations with Beijing during a period of tense relations with Washington, the announcement represents the largest contract reached thus far. Pascal Soriot, CEO of AstraZeneca, stated that it was the business's biggest investment in China, where it has been the leading foreign pharmaceutical company for almost 30 years. About 12% of their revenue comes from China.
In addition, in August 2025, according to the data published by the Biospectrum Asia, the Asia Pacific region has experienced a surge in biotechnology company formation, with around 9,05 active life sciences startups operating in the region as of 2025, demonstrating rapid growth in biotech innovation and industrial establishment.
The U.S. adult bovine serum market is driven by strong presence of biopharmaceutical and biotechnology companies, high investment in biomedical research & development and growing demand for cell-based research and advanced treatments. Moreover, due to growing prevalence of the chronic diseases such as diabetes, cancer and cardiovascular disorders has accelerated pharmaceutical R&D activities. As bovine serum is used extensively during laboratory-stage drug development and toxicity testing, the rise in disease-related research stimulates market growth. For instance, in March 2025, U.S. Centers for Disease Control and Prevention it has been estimated that the main causes of death and disability in the US are chronic illnesses like diabetes, cancer, and heart disease. Additionally, they are major contributors to the USD 4.9 trillion annual health care costs in the country. Over half of American adults have two or more chronic diseases, and three out of four have at least one. Over 90% of persons over 65 suffer from at least one chronic illness. Over 75% of midlife people between the ages of 35 and 64 suffer at least one illness. 60% of younger individuals (18–34 years old) have at least one illness.
China adult bovine serum market is driven by rapid expansion of biotechnology and biopharmaceutical industries. In China, both private and public sectors are pouring resources into genomics, life sciences, and cell-based technologies. This surge in investment is directly boosting the use of bovine serum in academic and laboratory settings. The Chinese government is supporting this effort with strong funding and biotech-friendly policies, such as innovation initiatives, bioparks, and a regulatory framework intended to promote pharmaceutical manufacture and biomedical advancements. Consequently, the adult bovine serum market is experiencing substantial growth. This expansion is driven by a combination of factors: the increasing volume of biomedical research and development, the rapid growth of the pharmaceutical and biotechnology sectors, strong government support for life sciences, and a rising need for vaccines, biologics, and regenerative medicine treatments.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 148.3 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.7% | 2033 Value Projection: | USD 217.6 Mn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
HiMedia Laboratories, Sartorius AG, Thermo Fisher Scientific, Auckland BioSciences Ltd., Moregate Biotech, Bovogen Biologicals, Merck KGaA, Capricorn Scientific GmbH, Gemini Bio, ROCKY MOUNTAIN BIOLOGICALS, Otto Chemie Pvt. Ltd, CellSera Australia, Serana Europe GmbH, TRINA BIOREACTIVES AG, and WISENT BIOPRODUCTS |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Due to increasing establishment of biopharmaceutical manufacturing infrastructure globally there is remarkable rise in the demand for adult bovine serum. Rising production of vaccines & cell-based therapies and establishment of contract development and manufacturing organizations is other major factor contributing to the growth of the market. Private and government investors across regions such as Asia Pacific, North America and Europe are heavily investing in research institutes, biotechnology parks, and advanced biomanufacturing hubs. These investment focus on empowering the domestic capabilities in biomedical research and biologics production.
Due to rapid expansion of global vaccine manufacturing capacity, there is significant rise in the demand for the cell culture media used in vaccine development and production which has created significant opportunity for the growth of the adult bovine serum market in the near future. Adoption of new trends like expansion of viral vaccine production utilizing mammalian cell lines has estimated to drive the growth of the adult bovine serum market in the near future. Pharmaceutical companies and governments across regions such as Asia-Pacific, North America and Europe are heavily investing in building new vaccine manufacturing plants to strengthen pandemic preparedness and public infrastructure.
Emerging markets such as countries in Latin America, Asia-Pacific, and parts of the Middle East are witnessing rapid growth in pharmaceutical and biotechnology industries. Increasing in investments in life science research and development all over the world is strengthening their capabilities in biomedical due to which the demand for bovine serum has increased. Growth of vaccine and biologics manufacturing, rising healthcare demand and regulatory support of various countries has created significant opportunity for the growth of the market in the near future.
Share
Share
About Author
Abhijeet Kale is a results-driven management consultant with five years of specialized experience in the biotech and clinical diagnostics sectors. With a strong background in scientific research and business strategy, Abhijeet helps organizations identify potential revenue pockets, and in turn helping clients with market entry strategies. He assists clients in developing robust strategies for navigating FDA and EMA requirements.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
